sprite-preloader
Anzeige
Mehr »
Sonntag, 18.11.2018 Börsentäglich über 12.000 News von 598 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen
13.07.2018 | 16:20
(9 Leser)
Schrift ändern:
(0 Bewertungen)

ACCESSWIRE·Mehr Nachrichten von ACCESSWIRE

All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com

EDINA, MN / ACCESSWIRE / July 13, 2018 / PetVivo Holdings, Inc. (OTC PINK: PETV), (www.petvivo.com) an emerging biomedical device company, is happy to announce today that it will be presenting at the 144th NIBA Investment Conference being held on July 16-17th, 2018 at Crown Plaza Times Square in New York City. The company will be presenting at 12:15 PM EDT/ 9:15 AM PDT on July 17th, 2018. John Lai, its President, will be presenting as well as meeting with investors.

For more information about NIBA or participating in our upcoming New York Conference on July 16-17, 2018 please visit www.nibanet.org or contact us at emily@nibanet.org or 706-208-9620.

Sponsors:

Hanover International

Island Stock Transfer

Sheppard Mullin

Alt 5 Sigma

C6 Capital

Carmel, Milazzo & DiChiara LLP

The CFO Squad

Chinese Investors Inc.

RRBB Accountants and Advisors

Thayer O'Neal

Atlas Consulting

BANQ

Consilium

Duane Morris

Equities

Issuer Direct

New to the Street

Four Springs Capital Trust

News Compliments of ACCESSWIRE.

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTC PINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company's product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company's products, production processes and biomaterials. PetVivo's lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.

About NIBA

For over 40 years, The National Investment Banking Association (NIBA) has been a not-for-profit association for the micro-cap and small-cap investment community and has hosted 144 investment conferences featuring public and private micro-cap and small-cap companies seeking access to the financial industry.

NIBA's member firms have successfully completing thousands of transactions totaling over $17 billion in new capital for emerging growth companies and are responsible for 90% of all IPOs under $20 million. We are thousands of investment professionals representing over 60 key industry services and includes over 8,800 registered representatives that have over $78 billion assets under management.

Petvivo Holdings, Inc.

Contact:

Wes Hayne
CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
Main: 962-405-6216
Direct: (763) 443-7272

SOURCE: PetVivo Holdings, Inc.


© 2018 ACCESSWIRE